RSV NEWCO
RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.
RSV NEWCO
Industry:
Health Care Health Diagnostics Medical Medical Device
Status:
Active
Total Funding:
50 K USD
Similar Organizations
Neurava
Neurava is working to develop a first of its kind, wearable diagnostic for epilepsy patients, including those at risk of SUDEP.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
VigorSential
VigorSential is Testing and developing a low-dose vaccine to control a bacterium mainly affecting cattle.
Xip
Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - RSV NewCo